Connect with us

Hi, what are you looking for?

Clinical Trials

EMPOWER Trial to Study Carillon Mitral Contour System

Cardiac Dimensions has announced the launch of the US pivotal study the EMPOWER trial, evaluating the Carillon mitral contour system for the treatment of heart failure patients with early-stage functional mitral regurgitation (FMR).

EMPOWER Trial to Study Carillon Mitral Contour System

This blinded, randomised trial will compare the Carillon treatment to a sham-controlled group treated with optimal medical management according to established heart failure guidelines. During development of the trial design, Cardiac Dimensions analysed an extensive amount of data from more than 250 study patients previously enrolled in over four similar trials. Based on these analyses, the device safety profile, and the company’s recent publications, the trial will focus on this extremely large patient population with limited other therapeutic alternatives.

Consistent with prior trials, Cardiac Dimensions will use third-party monitoring, core lab review and external safety reviews, which will produce the most scientifically rigorous clinical data to date in the investigation of heart failure patients with FMR. The combination of quality data, along with the trial being the only blinded, randomised, sham-controlled study performed in the mitral valve space, will make the EMPOWER trial a landmark clinical study in the area of heart failure.

“The launch of our US study represents a significant milestone for the company and big step forward to being able to offer the Carillon therapy to a patient population in need,” said Rick Wypych, Cardiac Dimensions president and chief executive officer. “It is interesting that despite just announcing the trial, we are already seeing overwhelming interest from our sites and the physician community, which is a clear testament to the need for additional device therapies for heart failure patients with early-stage FMR.”

The international trial is expected to randomise 300 patients at up to 75 sites. The study has primary safety and efficacy endpoints at 12 months and will follow the randomised patients out to five years to document long-term safety and clinical status.

“I am very excited to launch the EMPOWER trial,” said Samir Kapadia, interventional cardiologist, professor of medicine and chairman of the Department of Cardiovascular Medicine at Cleveland Clinic, Cleveland, USA and the national principal investigator of the EMPOWER trial. “This will be the first time where we are able to study early intervention with a device in heart failure. The Carillon device will be used to treat heart failure patients with mild and moderate functional mitral regurgitation. This is an extremely large patient population that is currently not being studied by other novel therapies. It will be phenomenal to study the efficacy of the Carillon device in the EMPOWER trial—a rigorously designed, randomised, double blinded, and sham-controlled multicentre clinical trial.”

Seen on Cardiovascular News: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Artificial Intelligence

The agency says stakeholders can use the principles to tailor and adopt good practices from other sectors to be used in the health tech...

Artificial Intelligence

The platform is ultimately meant to help accelerate clinical trials and increase the probability of success of future therapies for Parkinson’s, Alzheimer’s, Multiple Sclerosis,...


An Edinburgh researcher working on new therapies for difficult-to-treat cancers has become one of the first recipients of $20m worth of funding from an...

Digital Health

A freelance scientist from online platform Kolabtree has supported medical start-up Aires Medical with the development of a new oxygen concentrator.

You May Also Like

Artificial Intelligence

Digital Solutions In Healthcare Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm....


In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...

Digital Health

Software as a Medical Device (SaMD) is driving innovation in the HealthTech space and is more popular than ever — completely upending the way...